| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash | 315,087 | |||
| Due from sponsor-Sponsor | 566,269 | |||
| Prepaid expenses | 15,000 | |||
| Total current assets | 896,356 | |||
| Cash and investments held in trust account | 500,109,355 | |||
| Total assets | 501,005,711 | |||
| Accrued expenses | 5,843 | |||
| Accounts payable | 4,592 | |||
| Accrued offering costs | 113,162 | |||
| Over-allotment liability | 553,748 | |||
| Total current liabilities | 677,345 | |||
| Deferred underwriting fee payable | 17,500,000 | |||
| Total liabilities | 18,177,345 | |||
| Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of 10.00 and 0 per share as of september 30, 2025 and december 31, 2024, respectively | 500,109,355 | |||
| Ordinary shares, 0.0001 par value 220,000,000 shares authorized 15,575,000 and 14,375,000 shares issued and outstanding, excluding 50,000,000 and 0 shares subject to redemption as of september 30, 2025 and december 31, 2024, respectively | 1,557 | |||
| Accumulated deficit | -17,282,546 | |||
| Total shareholders deficit | -17,280,989 | |||
| Total liabilities and shareholders deficit | 501,005,711 | |||
Drugs Made In America Acquisition II Corp. (DMII)
Drugs Made In America Acquisition II Corp. (DMII)